As the omicron variant completes its sweep across the U.S., states with.

scarce supplies of monoclonal antibody therapies continue to use two.

infected with the delta variant, they shouldn’t use the others, said Dr.

And the delta variant is increasingly rare, accounting for 3% of cases in Louisiana, 7% in California, and 10% in Ohio, as examples4

“There’s not a medical justification based on the evidence on the Regeneron and Lilly products,” McClellan said.

variant is complicated, said Dr.

hospitals used about 72,000 doses of the Regeneron and.

Lilly monoclonal antibody therapies from Jan.

19, hospitals still had about 295,000 doses of the Regeneron and Lilly treatments on hand.

used the most courses of the Regeneron and Lilly treatments from Jan.

said he is not convinced that the Regeneron and Lilly products don’t

In Florida, omicron accounted for 97% of cases as of Jan

antibody therapies paused shipments of the Regeneron and Lilly

effective against the surging omicron variant than the delta variant

could still help people in places where the delta variant persisted

Regeneron itself has said its antibody treatments are ineffective

against the omicron variant

monoclonal antibody treatments

three monoclonal antibody treatments would continue through Jan

despite the growing proportion of omicron cases

Monoclonal antibody treatments are lab-based molecules that mimic the

government has agreed to purchase millions of doses of the Regeneron

and Lilly products at a cost of about $2,100 per dose

long-acting injectable monoclonal antibody for immunocompromised people,

and Lilly products have offered varied reasons

delta infections continued to circulate locally; others said they felt

Regeneron and Lilly products during the most recent two weeks, and

these products right now based on the distribution of omicron vs

scarce doses of the monoclonal antibody treatments only when they’re

Patients infected with the delta variant were able to be treated with

number of omicron cases, said Pauline Lucatero, the clinic’s director